Transcription factor STAT3 as a novel molecular target for cancer prevention

Ailian Xiong, Zhengduo Yang, Yicheng Shen, Jia Zhou, Qiang Shen

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Signal Transducers and Activators of Transcription (STATs) are a family of transcription factors that regulate cell proliferation, differentiation, apoptosis, immune and inflammatory responses, and angiogenesis. Cumulative evidence has established that STAT3 has a critical role in the development of multiple cancer types. Because it is constitutively activated during disease progression and metastasis in a variety of cancers, STAT3 has promise as a drug target for cancer therapeutics. Recently, STAT3 was found to have an important role in maintaining cancer stem cells in vitro and in mouse tumor models, suggesting STAT3 is integrally involved in tumor initiation, progression and maintenance. STAT3 has been traditionally considered as nontargetable or undruggable, and the lag in developing effective STAT3 inhibitors contributes to the current lack of FDA-approved STAT3 inhibitors. Recent advances in cancer biology and drug discovery efforts have shed light on targeting STAT3 globally and/or specifically for cancer therapy. In this review, we summarize current literature and discuss the potential importance of STAT3 as a novel target for cancer prevention and of STAT3 inhibitors as effective chemopreventive agents.

Original languageEnglish (US)
Pages (from-to)926-957
Number of pages32
JournalCancers
Volume6
Issue number2
DOIs
StatePublished - 2014

Fingerprint

STAT3 Transcription Factor
Neoplasms
Neoplastic Stem Cells
Drug Discovery
Transducers
Disease Progression
Cell Differentiation
Transcription Factors
Maintenance
Cell Proliferation
Neoplasm Metastasis
Therapeutics

Keywords

  • Cancer prevention
  • STAT3
  • STAT3 inhibitors
  • Transcription factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Transcription factor STAT3 as a novel molecular target for cancer prevention. / Xiong, Ailian; Yang, Zhengduo; Shen, Yicheng; Zhou, Jia; Shen, Qiang.

In: Cancers, Vol. 6, No. 2, 2014, p. 926-957.

Research output: Contribution to journalArticle

Xiong, Ailian ; Yang, Zhengduo ; Shen, Yicheng ; Zhou, Jia ; Shen, Qiang. / Transcription factor STAT3 as a novel molecular target for cancer prevention. In: Cancers. 2014 ; Vol. 6, No. 2. pp. 926-957.
@article{cfed9900024346a78a51d3fbe1f0d54d,
title = "Transcription factor STAT3 as a novel molecular target for cancer prevention",
abstract = "Signal Transducers and Activators of Transcription (STATs) are a family of transcription factors that regulate cell proliferation, differentiation, apoptosis, immune and inflammatory responses, and angiogenesis. Cumulative evidence has established that STAT3 has a critical role in the development of multiple cancer types. Because it is constitutively activated during disease progression and metastasis in a variety of cancers, STAT3 has promise as a drug target for cancer therapeutics. Recently, STAT3 was found to have an important role in maintaining cancer stem cells in vitro and in mouse tumor models, suggesting STAT3 is integrally involved in tumor initiation, progression and maintenance. STAT3 has been traditionally considered as nontargetable or undruggable, and the lag in developing effective STAT3 inhibitors contributes to the current lack of FDA-approved STAT3 inhibitors. Recent advances in cancer biology and drug discovery efforts have shed light on targeting STAT3 globally and/or specifically for cancer therapy. In this review, we summarize current literature and discuss the potential importance of STAT3 as a novel target for cancer prevention and of STAT3 inhibitors as effective chemopreventive agents.",
keywords = "Cancer prevention, STAT3, STAT3 inhibitors, Transcription factors",
author = "Ailian Xiong and Zhengduo Yang and Yicheng Shen and Jia Zhou and Qiang Shen",
year = "2014",
doi = "10.3390/cancers6020926",
language = "English (US)",
volume = "6",
pages = "926--957",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Transcription factor STAT3 as a novel molecular target for cancer prevention

AU - Xiong, Ailian

AU - Yang, Zhengduo

AU - Shen, Yicheng

AU - Zhou, Jia

AU - Shen, Qiang

PY - 2014

Y1 - 2014

N2 - Signal Transducers and Activators of Transcription (STATs) are a family of transcription factors that regulate cell proliferation, differentiation, apoptosis, immune and inflammatory responses, and angiogenesis. Cumulative evidence has established that STAT3 has a critical role in the development of multiple cancer types. Because it is constitutively activated during disease progression and metastasis in a variety of cancers, STAT3 has promise as a drug target for cancer therapeutics. Recently, STAT3 was found to have an important role in maintaining cancer stem cells in vitro and in mouse tumor models, suggesting STAT3 is integrally involved in tumor initiation, progression and maintenance. STAT3 has been traditionally considered as nontargetable or undruggable, and the lag in developing effective STAT3 inhibitors contributes to the current lack of FDA-approved STAT3 inhibitors. Recent advances in cancer biology and drug discovery efforts have shed light on targeting STAT3 globally and/or specifically for cancer therapy. In this review, we summarize current literature and discuss the potential importance of STAT3 as a novel target for cancer prevention and of STAT3 inhibitors as effective chemopreventive agents.

AB - Signal Transducers and Activators of Transcription (STATs) are a family of transcription factors that regulate cell proliferation, differentiation, apoptosis, immune and inflammatory responses, and angiogenesis. Cumulative evidence has established that STAT3 has a critical role in the development of multiple cancer types. Because it is constitutively activated during disease progression and metastasis in a variety of cancers, STAT3 has promise as a drug target for cancer therapeutics. Recently, STAT3 was found to have an important role in maintaining cancer stem cells in vitro and in mouse tumor models, suggesting STAT3 is integrally involved in tumor initiation, progression and maintenance. STAT3 has been traditionally considered as nontargetable or undruggable, and the lag in developing effective STAT3 inhibitors contributes to the current lack of FDA-approved STAT3 inhibitors. Recent advances in cancer biology and drug discovery efforts have shed light on targeting STAT3 globally and/or specifically for cancer therapy. In this review, we summarize current literature and discuss the potential importance of STAT3 as a novel target for cancer prevention and of STAT3 inhibitors as effective chemopreventive agents.

KW - Cancer prevention

KW - STAT3

KW - STAT3 inhibitors

KW - Transcription factors

UR - http://www.scopus.com/inward/record.url?scp=84898909914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898909914&partnerID=8YFLogxK

U2 - 10.3390/cancers6020926

DO - 10.3390/cancers6020926

M3 - Article

VL - 6

SP - 926

EP - 957

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

ER -